

List of supporting information

Figure S1. ^1H NMR (400 MHz, CDCl_3) spectrum of **1**




Figure S2. ^{13}C NMR (100 MHz, CDCl_3) spectrum of **1**




Figure S3. HRESI (+) MS spectrum of **2**



Figure S4. ^1H NMR (400 MHz, Acetone- d_6) spectrum of **2**




Figure S5. ^{13}C NMR (100 MHz, Acetone- d_6) spectrum of **2**




Figure S6. HRESI (+) MS spectrum of **3**




Figure S7. ^1H NMR (400 MHz, CDCl_3) spectrum of **3**




Figure S8. ^{13}C NMR (100 MHz, CDCl_3) spectrum of **3**




Figure S9. (A, B) The effects of compound **2** on cellular SHP2/p-SHP2 expression.

(C) Cellular thermal shift assay between SHP2 and different dose compound 2.




Figure S10. Molecular docking of SHP099 with SHP2 (PDB ID: 5EHR, green dash, hydrogen bonds; yellow dash, π -cation interaction; purple dash, halogen bond; other residues, hydrophobic interactions)




Figure S11. Docking pose and affinity energy of compound 2 binding to SHP2 (PDB ID: 5EHR)

mode	affinity	dist from best mode	
	(kcal/mol)	rmsd l.b.	rmsd u.b.
1	-7.8	0.000	0.000
2	-7.6	2.492	6.095
3	-6.6	1.751	2.890
4	-6.5	3.859	6.203
5	-6.2	1.944	6.519
6	-5.9	4.057	6.126
7	-5.8	3.828	7.268
8	-5.8	1.571	3.171
9	-5.5	3.908	7.477

Figure S12. Docking pose and affinity energy of SHP099 binding to SHP2 (PDB ID: 5EHR)

mode	affinity	dist from best mode	
	(kcal/mol)	rmsd l.b.	rmsd u.b.
1	-10.9	0.000	0.000
2	-10.2	1.381	1.794
3	-9.1	2.121	3.059
4	-8.5	1.423	2.327
5	-8.2	4.516	8.918
6	-8.0	4.272	8.692

Figure S13. Docking analysis of compound **2** binding to SHP2 (PDB ID: 5EHR) by PIPL





Figure S14. Docking analysis of compound **2** binding to SHP2 (PDB ID: 5EHR) by LigPlus






Figure S16. Docking analysis of SHP099 binding to SHP2 (PDB ID: 5EHR) by LigPlus




Figure S17. The relative expression of p-ERK, p-AKT and p-STAT3 after 72 h compound 2 treatment.




Figure S18. The relative expression of cleaved caspase 8,9,3 and cleaved PARP after 72 h compound 2 treatment.




Table S1. List of bonding interactions of SHP099 and compound 2 binding to SHP2 (PDB ID: 5EHR)

Compounds	Residues	Distance (Å)	Bond type
SHP099	Glu250	3.10	Hydrogen bonds

Compound 2	Thr108	3.13	Hydrogen bonds
	Phe113	2.79	Hydrogen bonds
	Thr253	3.30	Halogen bonds
	Arg111	3.60	π -cation interactions
	Lys492	< 4	Hydrophobic interactions
	Arg111	< 4	Hydrophobic interactions
	Pro491	< 4	Hydrophobic interactions
	Thr219	< 4	Hydrophobic interactions
	His114	< 4	Hydrophobic interactions
	Thr253	< 4	Hydrophobic interactions
	Glu249	< 4	Hydrophobic interactions
	THR218	2.59	Hydrogen bonds
	THR218	3.15	Hydrogen bonds
	GLU249	2.69	Hydrogen bonds
	His114	5.30	π -cation interactions
	His114	5.35	π -cation interactions
	Clu110	< 4	Hydrophobic interactions
	Arg111	< 4	Hydrophobic interactions
	Glu249	< 4	Hydrophobic interactions
	Gly246	< 4	Hydrophobic interactions
	Leu233	< 4	Hydrophobic interactions
	Glu250	< 4	Hydrophobic interactions
	Glu232	< 4	Hydrophobic interactions
	Thr219	< 4	Hydrophobic interactions
	Thr253	< 4	Hydrophobic interactions

Table S2. List of pharmacokinetics properties of compound **2**, including pharmacokinetic properties, lipophilicity, water solubility, drug-likeness, and medicinal chemistry.

Properties		Compound 2
Physicochemical	MW (g/mol)	324.37 g/mol
Properties	Heavy atoms	24
	Arom. Heavy atmos	9
	Rotatable bonds	0
	H-bond acceptors	4
	H-bond donors	2
	TPSA ($\leq 140 \text{ \AA}^2$)	70.67 \AA^2
Lipophilicity	Consensus Log $P_{o/w}$	3.74
Water solubility	Log S (ESOL)	Moderate
Pharmacokinetics	GI absorption	High
	BBB permeant	Yes
Drug-likeness	Lipinski	Yes
	Bioavailability score	0.55
Medi. Chemistry	PAINS	1 alert

